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Background: Thyroid dysfunction has been described to be linked to a variety of cardiovascular morbidities. Through
this pathway thyroid function might also be associated with cardiorespiratory function and exercise capacity. So far
only few patient-studies with small study populations investigated the association between thyroid dysfunction and
exercise capacity. Thus, the aim of our study was to investigate the association of serum thyroid-stimulating hormone
(TSH) levels with lung function and cardiopulmonary exercise testing (CPET) in the general population.
Methods: Data from the two independent cross-sectional population-based studies (Study of Health in Pomerania
[SHIP] and SHIP-Trend-0) were pooled. SHIP was conducted between 2002 and 2006 and SHIP-Trend-0 between 2008
and 2012. Participants were randomly selected from population registries. In total, 4206 individuals with complete data
were available for the present analysis. Thyroid function was defined based on serum TSH levels. Lung function was
evaluated by forced expiratory volume in 1 s and forced vital capacity. CPET was based on symptom limited exercise
tests on a bicycle in a sitting position according to a modified Jones protocol. Associations of serum TSH levels with
lung function and CPET parameters were analysed by multivariable quantile regression adjusted for age, sex, height,
weight, use of beta blockers, smoking status, and physical activity.
Results: Serum TSH levels, used as continuously distributed variable and categorized according to the clinical cut-offs
0.3 and 3.0 mIU/L or according to quintiles, were not consistently associated with parameters of lung function or CPET.
Conclusions: Our results suggest that thyroid dysfunction is not associated with lung function and cardiopulmonary
exercise capacity in the general population.
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Thyroid dysfunction has been described to be linked to
a variety of cardiovascular morbidities [1]. For hyperthy-
roidism associations with atrial fibrillation [2], left ven-
tricular hypertrophy [3], carotid atherosclerosis [4,5],
and high fibrinogen levels [6] have been reported. On
the other hand hypothyroidism is associated with altered
lipid metabolism [7,8], endothelial dysfunction [9], and* Correspondence: till.ittermann@uni-greifswald.de
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unless otherwise stated.an overall increased atherosclerotic risk [10]. The associ-
ation between thyroid dysfunction and cardiovascular
diseases might in part be linked with or paralleled by re-
duced lung function which is strongly associated with in-
creased cardiovascular morbidity and mortality [11,12]. In
fact, evidence for such an association exists. Thus, thyroid
dysfunctions are for example associated with pulmonary
hypertension [13]. It has also been demonstrated that
hyperthyroidism is accompanied by a reduced muscle
strength resulting in impaired ventilation under exer-
cise [14,15]. Furthermore, it has been demonstrated
that the cardiovascular capacity is reduced in hyperthyroidral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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otropic regulation [16] and can be restored by treat-
ment with antithyroid medication [17]. Likewise, also
hypothyroid states have been shown to be related to
lung function impairment. A link between hypothyroidism
and decreased lung function might be explained by al-
veolar hypoventilation, decreased inspiratory muscle
strength, and decreased respiratory rates [18,19]. In
hypothyroid patients it has been shown that treatment
with thyroxine results in an improved exercise cardio-
pulmonary reserve [20].
So far several patient-studies with small study popula-
tions investigated the association of hypo- and hyperthy-
roidism with lung function [18,21-26] and exercise
capacity [23,27-30]. While most of the patient studies
demonstrated significant associations between thyroid
dysfunction and lung function [18,22-24,26], results
from studies investigating the impact of hyperthyroidism
on exercise capacity are inconsistent [23,30]. Kahaly
et al. [23] showed a reduced exercise capacity in patients
with untreated overt hyperthyroidism, whereas Portella
and coworkers did not demonstrate an association be-
tween hyperthyroidism and exercise capacity in female
patients with subclinical hyperthyroidism [30]. Regard-
ing hypothyroidism, one study [27] showed an impaired
exercise capacities in patients under long-term levothyr-
oxine treatment for nontoxic goiter or differentiated thy-
roid carcinoma in comparison to healthy controls. In
agreement with this, another study [28] demonstrated
reduced exercise capacities in patients with exogenous
subclinical hypothyroidism compared to controls, but
one-year-change of exercise capacity did not differ
among groups of levothyroxine treatment and placebo
groups [28]. In line with this, another study reported
an association between low free triiodothyronine levels
and impaired exercise capacity in patients with heart
failure [29].
The discrepancy in results among previous studies in-
vestigating associations between thyroid dysfunction and
exercise capacity is probably referred to the fact that all
those studies were conducted in selected patient popula-
tions. Furthermore, it is unclear whether the significant
findings between thyroid dysfunction and lung function
detected in the patient studies can be extended to the
general population, because potential associations of
thyroid dysfunction with lung function and exercise
capacity has never been analysed in population-based
samples. Against this background we aimed to investi-
gate the association of thyroid function state as deter-
mined by serum thyroid-stimulating hormone (TSH)
levels with parameters of lung function and cardio-
pulmonary exercise testing (CPET) in two independ-
ent population-based studies conducted in Northeast
Germany.Methods
Study population
Analyses are based on data from two independent co-
horts of the Study of Health in Pomerania (SHIP), con-
ducted in Northeast Germany [31]. In the first SHIP
cohort (SHIP-0) 6267 eligible subjects were randomly
selected from population registries. Of those, 4308 indi-
viduals were examined between 1997 and 2001 (68.8%).
Between 2002 and 2006 all participants were re-invited
for an examination follow-up (SHIP-1), in which 3300
subjects aged 25 to 85 years took part (1589 men and
1711 women; 83.5% of all eligible subjects). Of those,
1708 individuals volunteered for CPET and spirometry
(52.0%).
For the second SHIP cohort (SHIP-Trend-0) 8800 eli-
gible subjects were randomly selected from population
registries and 4422 individuals aged 20 to 81 years par-
ticipated (response 50.3%) between 2008 and 2012. In
SHIP-Trend-0 in total 2678 individuals volunteered
CPET and spirometry examinations (60.6%). All partici-
pants gave informed written consent and both studies
followed the recommendations of the Declaration of
Helsinki and were approved by the Ethics Committee of
the University of Greifswald.
From SHIP-1 and SHIP-Trend-0, we excluded 34 and
146 participants, respectively, with missing data in any
of the considered variables. Furthermore, we excluded
22 individuals in SHIP-Trend-0, who weighed more than
120 kg and therefore had to use a recumbent bike for
spiroergometry. Measurements from the recumbent bike
are not comparable with results from the standard cycle
ergometer. In total, our analyses are based on a study
population consisting of 4184 individuals (2110 women).
Assessments
Physical activity and smoking status were assessed by
computer-assisted personal interviews. Subjects who
participated in physical training during summer or win-
ter for at least one hour a week were classified as being
physically active. Smokers were categorized into three
categories (lifetime non-smokers, former smokers, and
current smokers). Beta blocker use was defined by the
anatomic-therapeutical-chemical (ATC) code C07. Height
and weight were measured for calculation of the body
mass index (BMI).
Blood samples were taken non-fasting in SHIP-1. In
SHIP-Trend-0 75% of the blood samples were taken fast-
ing. Serum TSH levels were measured by immunochem-
iluminiscent procedures (SHIP-1: Immulite 2000, Third
Generation, DPC, Los Angeles, USA; SHIP-Trend-0:
Vista, Siemens, Eschborn, Germany). In SHIP-Trend-0
median serum TSH levels were comparable between
fasting and non-fasting individuals (1.15 mIU/L vs 1.10
mIU/L). Low and high serum TSH levels were defined
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Baskin et al. [32]. Furthermore, individuals were classi-
fied into five groups according to TSH quintiles.
In both studies, CPET was performed using the same
calibrated electromagnetically braked cycle ergometer
(Ergoselect 100, Ergoline, Germany) with a physician in
attendance according to a modified Jones protocol:
3 min of rest, 1 min of unloaded cycling at 60 rpm,
stepwise increases in work load of 16 W/min until
symptom-limited or terminated by the physician due to
chest pain or ECG abnormalities, and 5 min of recovery
[33]. From spirometry we used forced expiratory volume
in 1 s (FEV1), forced vital capacity (FVC), and its ratio
(FEV1/FVC) to characterize resting lung function [34].
Furthermore, we used the following parameters from
CPET: peak oxygen uptake (peakVO2), oxygen uptake at
anaerobic threshold (VO2@AT), slope of the efficiency
of ventilation in removing carbon dioxide (VE vs. VCO2
slope), oxygen pulse (O2HR), maximum power, and ex-
ercise duration [35].
Statistical analyses
Continuous variables are expressed as median, 25th, and
75th percentile; categorical variables as absolute num-
bers and percentages. Serum TSH levels were associated
with parameters of CPET and spirometry by median
regression adjusted for age, sex, height, weight, beta
blocker use, smoking status, physical activity, study
(SHIP-1 or SHIP-Trend-0), and time between core
examination and CPET examination. Median regression
was used, because for some outcomes the residuals were
not normally distributed. Participants significantly dif-
fered from non-participants of the CPET examination
regarding serum TSH levels, age, body mass index, beta
blocker use, physical activity, current smoking, and edu-
cation [36]. Particularly, participating individuals were
younger, had a lower BMI, and were less often smokers
and physically inactive than non-participants. To ac-
count for these differences we applied inverse probability
weights. This procedure gives individuals from groups,
which are more likely to drop out, a stronger weight in
the analyses compared to individuals from groups with
less drop outs. To account for possible non-linear rela-
tionships between serum TSH levels or any of the con-
founders with the respective outcome multivariable
fractional polynomials were tested [37]. A p < 0.05 was
considered as statistically significant. All analyses were
carried out using Stata 12.1 (Stata Corporation, College
Station, TX, USA).
Results
Serum TSH levels were higher in SHIP-Trend-0 than in
SHIP-1 (1.14 mIU/L vs. 0.78 mIU/L). Measurements of
CPET were comparable among the two studies, butFEV1/FVC was 5.5% lower in SHIP-Trend-0 than in
SHIP-1. In the pooled population most measurements
of spirometry (FEV1 and FVC) and CPET (peakVO2,
VO2@AT, O2HR, maximum power, and exercise duration)
were lower in individuals with low TSH compared to indi-
viduals with serum TSH levels in the reference range,
while there were substantial differences between individ-
uals with high TSH and individuals with TSH in the refer-
ence range only for VO2@ATand O2HR (Table 1).
Serum TSH levels and lung function
Serum TSH levels over the full range were significantly as-
sociated with FEV1/FVC in a linear fashion, while there
was no association to FEV1 and FVC values (Table 2). In
comparison to serum TSH levels within the reference
range, FEV1, FVC, and FEV1/FVC values did neither differ
for low nor for high serum TSH levels. Serum TSH levels
within the reference range were significantly associated
with FEV1/FVC, but not with FEV1 and FVC values. For
FEV1, FVC, and FEV1/FVC there were no significant dif-
ferences between the third and the other TSH quintiles
(Table 3).
Serum TSH levels and CPET
Serum TSH levels over the full range were inversely as-
sociated with O2/HR in multivariable linear regression,
but there was no association with peakVO2, VO2@AT,
VE vs. VCO2 slope, maximum power, and exercise dur-
ation (Table 2). Compared to serum TSH levels within
the reference range, CPET parameters did neither sig-
nificantly differ for low nor for high serum TSH levels.
Likewise, serum TSH levels within the reference range
were not associated with any of the CPET parameters.
Regression analyses with quintiles of serum TSH levels
revealed in total four significant associations to CPET
parameters (Table 3). PeakVO2 values were significantly
lower in the 2nd TSH quintile in comparison to the 3rd
TSH quintile, but peakVo2 values did not significantly
differ between the 1st and the 3rd TSH quintile. Max-
imum power and exercise duration values were signifi-
cantly lower in the 1st TSH quintile than in the 3rd
TSH quintile. O2/HR values were significantly lower in
the 5th than in the 3rd TSH quintile.
For sensitivity analysis we excluded all individuals
treated with thyroid medication. In this subpopulation
regression results did not differ significantly from those
in the total population (Additional file 1: Table S1).
Discussion
In data pooled from two independent large population-
based studies from Northeast-Germany we detected no
consistent associations between thyroid function state as
measured by serum TSH levels and lung function or ex-
ercise capacity. The statistically significant results that
Table 1 Characteristics of the pooled study population stratified by serum TSH levels
0.3 < TSH ≤ 3.0 mIU/L TSH ≤ 0.3 mIU/L TSH > 3.0 mIU/L
(n = 3877) (n = 200) (n = 107)
Age; years 52 (41; 63) 57 (47; 68) 48 (37; 58)
Males 1949 (50.3%) 85 (42.5%) 40 (37.4%)
BMI; kg/m2 27.3 (24.5; 30.6) 27.7 (24.3; 31.0) 26.9 (23.6; 30.0)
Physical activity 1986 (51.2%) 86 (43.0%) 61 (57.0%)
Former smokers 1395 (36.0%) 91 (45.5%) 35 (32.7%)
Current smokers 861 (22.2%) 33 (16.5%) 23 (21.5%)
Systolic blood pressure, mmHg 128 (116; 140) 127 (114; 140) 124 (113; 137)
Diastolic blood pressure, mmHg 78 (72; 85) 79 (72; 85) 78 (72; 85)
Beta blocker use 862 (22.2%) 58 (29.0%) 22 (20.6%)
Thyroid medication use 363 (9.4%) 59 (29.5%) 24 (22.4%)
Education
- < 10 years 900 (23.2%) 69 (34.5%) 12 (11.2%)
- = 10 years 1947 (50.2%) 96 (48.0%) 57 (53.3%)
- > 10 years 1029 (26.6%) 35 (17.5%) 38 (37.5%)
FEV1; l 3.2 (2.6; 3.8) 3.0 (2.5; 3.6) 3.3 (2.7; 3.8)
FVC; l 4.0 (3.3; 4.8) 3.6 (3.0; 4.4) 4.0 (3.3; 4.7)
FEV1/FVC; % 81.8 (77.5; 85.8) 82.6 (78.4; 86.6) 81.4 (77.8; 85.3)
peakVO2; ml/min 1900 (1500; 2400) 1703 (1450; 2092) 1905 (1507; 2450)
VO2@AT; ml/min 1000 (850; 1200) 975 (800; 1175) 950 (850; 1200)
O2HR; ml/beat 12.8 (10.4; 15.6) 12.0 (10.5; 15.0) 12.4 (9.5; 14.9)
VE vs. VCO2 slope 26 (24; 29) 26 (24; 29) 26 (24; 29)
Maximum power; watt 148 (116; 196) 132 (116; 164) 148 (116; 180)
Exercise duration; minutes 9.1 (7.2; 11.4) 8.1 (6.4; 10.1) 9.1 (7.2; 11.1)
Median, 25th, and 75th percentile (continuous variables); absolute numbers and percentages (categorical variables).
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referred to the problem of multiple testing. The likeli-
hood to detect a significant association increases with the
number of tests performed. If we assume the Bonferroni
corrected p-value threshold of 0.0007, none of the testsTable 2 Association between TSH and parameters of spirome
Model 1
TSH full range TSH <
β (95%-CI) β (95
FEV1; l −0.01 (−0.04; 0.01) 0.06 (−0.
FVC; l −0.003 (−0.034; 0.028) 0.03 (−0.
FEV1/FVC; % −0.35* (−0.65; −0.06) −0.06 (−1
peakVO2; ml/min 1.2 (−18.1; 20.4) 19.2 (−46
VO2@AT; ml/min −4.7 (−14.8; 5.5) 14.0 (−19
O2HR; ml/beat −0.11* (−0.22; −0.01) 0.33 (−0.
VE vs. VCO2 slope 0.11 (−0.06; 0.29) −0.44 (−1
Maximum power; watt 1.3 (−0.1; 2.7) 0.1 (−5
Exercise duration; minutes 0.02 (−0.08; 0.12) 0.02 (−0.
Median regression adjusted for age, sex, body mass index, beta blocker intake, smo
#Reference: TSH in the reference range.performed in our analysis would be statistically signifi-
cant. Furthermore, the detected significant associations
at the 0.05 α-level do not give a uniform picture. For ex-
ample, FEV1/FVC was related to serum TSH levels over
the full range and serum TSH levels within the referencetry and cardiopulmonary exercise testing
Model 2 Model 3
0.3# TSH > =3# TSH in the reference range
%-CI) β (95%-CI) β (95%-CI)
06; 0.17) −0.06 (−0.14; 0.02) 0.01 (−0.03; 0.04)
10; 0.17) −0.08 (−0.21; 0.04) 0.02 (−0.03; 0.06)
.23; 1.12) −0.78 (−2.02; 0.47) −0.48* (−0.91; −0.04)
.4; 84.8) 3.0 (−98.5; 104.5) 12.9 (−15.4; 41.3)
.3; 47.4) −9.3 (−52.0; 33.5) −4.2 (−18.2; 9.9)
14; 0.81) −0.31 (−0.88; 0.26) −0.08 (−0.25; 0.08)
.08; 0.19) 0.05 (−0.69; 0.79) 0.21 (−0.05; 0.46)
.7; 6.0) −0.4 (−11.1; 10.3) 1.9 (−0.1; 3.9)
33; 0.37) −0.16 (−0.62; 0.29) 0.07 (−0.07; 0.20)
king status, physical activity, study and time between examinations; *p < 0.05;
Table 3 Association between quintiles of TSH and parameters of spirometry and cardiopulmonary exercise testing
First quintile# Second quintile# Fourth quintile# Fifth quintile#
(0 – 0.5745 mIU/L) (0.5745 – 0.839 mIU/L) (1.14 – 1.59 mIU/L) (1.59 – 10.00 mIU/L)
β (95%-CI) β (95%-CI) β (95%-CI) β (95%-CI)
FEV1; l 0.00 (−0.06; 0.07) 0.02 (−0.05; 0.08) −0.01 (−0.07; 0.05) 0.01 (−0.05; 0.07)
FVC; l −0.01 (−0.08; 0.06) −0.01 (−0.08; 0.07) −0.002 (−0.073; 0.069) 0.005 (−0.073; 0.083)
FEV1/FVC; % 0.31 (−0.38; 0.99) −0.02 (−0.75; 0.71) −0.14 (−0.80; 0.52) −0.45 (−1.13; 0.24)
peakVO2; ml/min −32.3 (−73.1; 8.5) −48.5* (−89.2: −7.9) −35.3 (−79.8; 9.3) −16.6 (−60.5; 27.4)
VO2@AT; ml/min 2.4 (−21.8; 26.6) −3.7 (−28.3; 20.9) −11.1 (−34.5; 12.4) −8.2 (−30.7; 14.3)
O2HR; ml/beat −0.06 (−0.35; 0.24) −0.25 (−0.53; 0.02) −0.28 (−0.56; 0.01) −0.32* (−0.59; −0.05)
VE vs. VCO2 slope −0.20 (0.66; 0.27) −0.24 (−0.71; 0.23) 0.20 (−0.23; 0.64) 0.04 (−0.40; 0.48)
Maximum power; watt −3.7* (−7.1; −0.3) −3.1 (−6.7; 0.5) −2.7 (−6.0; 0.6) 0.2 (−3.2; 3.5)
Exercise duration; minutes −0.22* (−0.41; −0.03) −0.15 (−0.35; 0.04) −0.18 (−0.39; 0.03) −0.07 (−0.29; 0.15)
Median regression adjusted for age, sex, height, weight, beta blocker intake, smoking status, physical activity, and time between examinations.
*p < 0.05.
#Reference: Third quintile 0.839 – 1.14 mIU/L.
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roidism. Likewise, inconsistent findings were detected for
peakVO2, O2/HR, and maximum power. Thus, our re-
sults suggest that there is no evidence of an association
between thyroid dysfunction and lung function and
CPET in the general population.
Thyroid dysfunction and lung function
There are several small patient studies that investigated
putative associations between hypo- or hyperthyroidism
with spirometry parameters [18,21-26]. In two of these
studies patients with hypothyroidism had lower FEV-1
and FVC values than euthyroid controls [24,26], while in
two other patient studies such associations were not de-
tected [21,25]. Differences between these patient studies
might be related to the low number of included individ-
uals and different medical conditions of individuals in
those studies. The studies, which did not detect an associ-
ation between hypothyroidism and lung function, consist
of individuals with COPD [25] or of individuals with
treated hypothyroidism [21], while the studies, which de-
tected significant associations, included individuals with
untreated hypothyroidism [24,26]. On the other hand, pa-
tient studies consistently reported a lower lung function
in hyperthyroid patients than in euthyroid controls
[22,23,26]. Thus, the findings of the patient studies
hypothesize that there might also be an association be-
tween thyroid dysfunction, especially hyperthyroidism,
and lung function. In our study, however, we did not de-
tect a significant association between serum TSH levels
and lung function based on a comprehensive set of spir-
ometry parameters. An explanation for the lack of a sig-
nificant finding might be that the number of individuals
with clinically relevant thyroid dysfunction might be rela-
tively low as can be seen by the relatively low proportion
of thyroid medication intake in individuals with serumTSH levels outside the reference range. Even though we
have no serum free triiodothyronine (fT3) or thyroxine
(fT4) levels measured in SHIP-1 and SHIP-Trend-0 to dis-
tinct overt and subclinical forms of thyroid dysfunction,
findings from SHIP-0, the baseline of SHIP-1, indicate that
the prevalence of overt thyroid dysfunctions might be low
in our study population. Thus, in SHIP-0 there were only
28 individuals (0.7%) with overt hyperthyroidism and 36
individuals (0.9%) with over hypothyroidism. Hence, the
results of our study might argue that lung function is not
reduced due to mild forms of hypo- or hyperthyroidism.
Thyroid dysfunction and CPET
With respect to the potential association between hyper-
thyroid dysfunction and CPET, the findings of our study
are in agreement with a small study [30], in which exercise
tolerance of 14 females with subclinical hyperthyroidism
did not differ from 15 age-matched apparently healthy
controls. In contrast, another study demonstrated a re-
duced exercise capacity in 42 patients with untreated
hyperthyroidism that was significantly increased 6 months
later when euthyroidism was restored by methimazole
[23]. Similarly, another study [38] reported a reduced ex-
ercise capacity in 15 hyperthyroid patients. Exercise test-
ing was repeated in nine of these subjects after treatment
with carbimazole, showing markedly improved exercise
parameters [38]. The discrepancy between our study and
the results of the other two studies [23,38] might be re-
ferred mainly to the different study populations. Those
studies [23,38] analysed data of patients with subclinical
or overt hyperthyroidism and/or the effects of restoration
of euthyroidism. In contrast, our analyses are based on a
population based sample which is characterized by fewer
subjects with clinically relevant hyperthyroid states, which
might explain the lack of a significant finding in our
analyses.
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able that, in contrast to our study, found consistent
associations with exercise capacity. Thus, one study
demonstrated lowered exercise capacity in hypothyroid
patients under long-time levothyroxine treatment [27].
Another study showed a reduced exercise tolerance in
hypothyroid patients with Hashimoto thyroiditis in com-
parison to matched controls at baseline but no changes
in these patients after one year use of levothyroxine [28].
The results of those studies [27,28] might argue for an
impaired exercise capacity only in individuals with overt
states of hypothyroidism and/or long-time thyroid hor-
mone treatment.
Strength and limitations
Strengths of our study are its population-based design,
which allows generalization for the background popula-
tion of Northeast Germany, and the large number of in-
dividuals included. A limitation is that we were not able
to divide hypo- and hyperthyroidism into its overt and
subclinical forms due to the lack of free triiodothyronine
and free thyroxine levels. However, results from the
baseline SHIP examinations, for which these measure-
ments were available, indicate that most of the partici-
pants with thyroid dysfunction have the subclinical form
[39]. Furthermore, there were relevant differences be-
tween participants and non-participants of the CPET ex-
aminations. We account for these differences in our
analysis by applying inverse probability weights.
Conclusions
Our results suggest that thyroid dysfunction is not asso-
ciated with lung function and CPET in the general
population.
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